RNAi, una nueva estrategia terapéutica en Carcinoma Anaplásico de Tiroides
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/20670
Ficheiros no ítem
Metadatos do ítem
Título: | RNAi, una nueva estrategia terapéutica en Carcinoma Anaplásico de Tiroides |
Autor/a: | Rodrigues, Joana Sousa |
Dirección/Titoría: | Álvarez Villamarín, Clara Cameselle Teijeiro, José Manuel |
Centro/Departamento: | Universidade de Santiago de Compostela. Centro Internacional de Estudos de Doutoramento e Avanzados (CIEDUS) Universidade de Santiago de Compostela. Escola de Doutoramento Internacional en Ciencias da Saúde Universidade de Santiago de Compostela. Programa de Doutoramento en Endocrinoloxía |
Palabras chave: | cáncer anaplásico de tiroides | RNA de interferencia dsRNAi | proteómica | catástrofe mitótica | |
Data: | 2019 |
Resumo: | Anaplastic thyroid carcinoma (ATC) has a low incidence but is lethal, with rare cases of survival for more than a few months. There are no specific clinical trials nor effective therapies. Our group has established a system where thyroid cancer from patients is cultivated in a standardized way parallelly with their benign/normal samples in order to study specific differences from the cancer. Through differential proteomics between cancer and benign samples, a PIAS2 protein more expressed in thyroid cancer was discovered. An RNA interference (dsRNAi) specific for beta isoform was designed. PIAS2b dsRNAi induces death of anaplastic cells without affecting differentiated carcinoma cells. Through cellular and molecular biology techniques and an in vivo orthotopic PDX model it was demonstrated that PIAS2 is essential for the mitosis of the anaplastic cells and their reduction induces mitotic catastrophe. PIAS2b is a specific therapeutic target in ATC. |
URI: | http://hdl.handle.net/10347/20670 |
Dereitos: | Attribution-NonCommercial-NoDerivatives 4.0 Internacional |
Coleccións
-
- Área de Ciencias da Saúde [1262]
O ítem ten asociados os seguintes ficheiros de licenza: